Stocks · News reference
William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Beta Bionics reported Q3 2026 net sales of $35.5 million and updated its full-year 2026 revenue guidance to $124 million–$126 million. The company also announced the withdrawal of its 510(k) application for the 3D Intelligence algorithm to provide additional validation data.
A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels and causing hundreds of life-threatening hypoglycemic events. The company allegedly failed to disclose thousands of customer complaints to the FDA and misrepresented the scope of FDA Form 483 findings. Investors who purchased stock between July 30, 2025 and February 24, 2026 can join the lawsuit with a November 3, 2026 deadline to request lead plaintiff status.
Filed: 2026-10-27 AccNo: 0001171843-26-006856 Size: 356 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Jefferies analyst Michael Toomey initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Buy rating and announces Price Target of $30.
Tandem Diabetes Care (NASDAQ:TNDM) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time